Osimertinib and Tegavivint as First-Line Therapy for the Treatment of Metastatic EGFR-Mutant Non-small Cell Lung Cancer
A Phase Ib Study of AZD9291 (Osimertinib) and BC2059 (Tegavivint) as First-Line Therapy in Patients With Metastatic EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC)
Sponsor: Ohio State University Comprehensive Cancer Center
Listed as NCT04780568, this PHASE1 trial focuses on Metastatic Lung Non-Small Cell Carcinoma and Stage IV Lung Cancer AJCC v8 and remains actively recruiting participants. Sponsored by Ohio State University Comprehensive Cancer Center, it has been updated 7 times since 2022, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
7 versions recorded-
Jan 2026 — Present [monthly]
Recruiting PHASE1
-
Feb 2025 — Jan 2026 [monthly]
Recruiting PHASE1
-
Sep 2024 — Feb 2025 [monthly]
Recruiting PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Recruiting PHASE1
-
Jan 2024 — Jul 2024 [monthly]
Recruiting PHASE1
▶ Show 2 earlier versions
-
Sep 2022 — Jan 2024 [monthly]
Recruiting PHASE1
Status: Not Yet Recruiting → Recruiting
-
Apr 2021 — Sep 2022 [monthly]
Not Yet Recruiting PHASE1
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Ohio State University Comprehensive Cancer Center
For direct contact, visit the study record on ClinicalTrials.gov .